Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Treasury Shares (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Treasury Shares for 5 consecutive years, with $163606.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 90.06% to $163606.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $163606.0, a 90.06% decrease, with the full-year FY2025 number at $163606.0, down 90.06% from a year prior.
  • Treasury Shares was $163606.0 for Q4 2025 at Relay Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.6 million in Q4 2024 to a low of $163606.0 in Q4 2025.
  • A 4-year average of $1.0 million and a median of $1.1 million in 2021 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: soared 718.1% in 2021, then crashed 90.06% in 2025.
  • Relay Therapeutics' Treasury Shares stood at $691205.0 in 2021, then surged by 126.67% to $1.6 million in 2022, then rose by 5.06% to $1.6 million in 2024, then plummeted by 90.06% to $163606.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Treasury Shares are $163606.0 (Q4 2025), $1.6 million (Q4 2024), and $1.6 million (Q4 2022).